Cadrenal Therapeutics, Inc. (CVKD) Stock Profile — Insider Trades & Financials

Net Income-$3.0M

EPS$-5.23

Market Cap$12.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Quang Pham

CEO & Executive Director

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Founded: 2022
Employees: 4
Headquarters

⚡

Core Efficiency

ROE?

-110.96%

ROA?

-70.24%

D/E Ratio?

0.58

📊

Profitability Ratios

Current Ratio?

2.72

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 26, 2026 (in 139 days)

Annual Report (10-K) — Estimated

Aug 26, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20254d after period end

Nov 10, 2025

10-QQ3 20250d after period end

Aug 11, 2025

10-QQ2 20250d after period end

May 8, 2025

10-QQ1 20250d after period end

Mar 13, 2025

10-KQ4 20240d after period end

Nov 7, 2024

10-QQ3 20240d after period end

Aug 7, 2024

10-QQ2 20240d after period end

May 9, 2024

10-QQ1 20240d after period end

Loading company sections...

Cadrenal Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness